{{Rsnum
|rsid=345013
|Chromosome=3
|position=145456001
|Orientation=minus
|GMAF=0.1102
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 3.1 | 23.1 | 73.8
| HCB | 0.0 | 31.1 | 68.9
| JPT | 2.3 | 36.4 | 61.4
| YRI | 0.0 | 12.7 | 87.3
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 31.1 | 68.9
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{GWAS Summary
|SNP=rs345013
|PubMedID=17903305
|Condition=Prostate cancer
|Gene=Intergenic
|Risk Allele=
|pValue=5.00E-006
|OR=NA
|95CI=
|OA=1
}}

{{PharmGKB
|RSID=rs345013
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17903305; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study (Initial Sample Size: 1,345 individuals (Framingham); Replication Sample Size: NR). This variant is associated with Prostate cancer.
|Drugs=
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356387
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs345013
|overall_frequency_n=14
|overall_frequency_d=128
|overall_frequency=0.109375
|n_genomes=10
|n_genomes_annotated=0
|n_haplomes=10
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}